Penumbra, Inc. (NYSE:PEN) Director Sells $3,405,240.00 in Stock

Penumbra, Inc. (NYSE:PEN) Director Arani Bose sold 12,000 shares of the stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $283.77, for a total value of $3,405,240.00. Following the sale, the director now owns 314,819 shares of the company’s stock, valued at approximately $89,336,187.63. The trade was a 3.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Penumbra Trading Down 0.9 %

NYSE PEN opened at $267.16 on Friday. The company has a current ratio of 6.01, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02. The business has a fifty day simple moving average of $274.55 and a 200 day simple moving average of $242.90. Penumbra, Inc. has a 12 month low of $148.00 and a 12 month high of $310.00. The firm has a market capitalization of $10.29 billion, a P/E ratio of 785.75, a PEG ratio of 2.83 and a beta of 0.51.

Penumbra (NYSE:PEN) last released its quarterly earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.09. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The company had revenue of $315.52 million for the quarter, compared to analyst estimates of $311.63 million. On average, analysts predict that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Analyst Ratings Changes

PEN has been the subject of several recent analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Penumbra in a research note on Wednesday, February 19th. Wells Fargo & Company raised their price objective on shares of Penumbra from $275.00 to $305.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 19th. Oppenheimer began coverage on shares of Penumbra in a research report on Tuesday, December 17th. They set an “outperform” rating and a $275.00 target price on the stock. Citigroup raised their price target on shares of Penumbra from $220.00 to $245.00 and gave the stock a “neutral” rating in a report on Wednesday, December 11th. Finally, Truist Financial upped their price objective on shares of Penumbra from $285.00 to $325.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Penumbra currently has an average rating of “Moderate Buy” and an average target price of $294.47.

Hedge Funds Weigh In On Penumbra

A number of hedge funds and other institutional investors have recently modified their holdings of PEN. True Wealth Design LLC bought a new stake in Penumbra during the third quarter worth $26,000. UMB Bank n.a. increased its position in shares of Penumbra by 57.4% during the 4th quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $46,000 after purchasing an additional 70 shares during the last quarter. Hurley Capital LLC bought a new stake in shares of Penumbra during the 4th quarter worth $56,000. Huntington National Bank boosted its holdings in shares of Penumbra by 138.7% in the 4th quarter. Huntington National Bank now owns 265 shares of the company’s stock worth $63,000 after buying an additional 154 shares during the last quarter. Finally, Mather Group LLC. increased its holdings in Penumbra by 208.0% during the fourth quarter. Mather Group LLC. now owns 308 shares of the company’s stock worth $73,000 after buying an additional 208 shares during the last quarter. Hedge funds and other institutional investors own 88.88% of the company’s stock.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.